Double negative T cells levels correlate with chronic graft-versus-host disease severity

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can eradicate several blood cancers otherwise incurable by chemotherapy alone, in large part due to the graft-versus-tumour effect1. Despite indisputable successes due to the graft-versus-tumour effect, the efficacy of allo-HSCT is hampered by cancer recurrence and the development of graft-versus-host disease (GVHD)2, 3. Notably, reduced intensity conditioning in lieu of myeloablative conditioning has improved patient survival following allo-HSCT by attenuating the acute toxic effects4.

Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Erin E. Hillhouse, St éphanie Thiant, Moutuaata M. Moutuou, Félix Lombard-Vadnais, Rachel Parat, Jean-Sébastien Delisle, Imran Ahmad, Denis-Claude Roy, Martin Guimond, Jean Roy, Sylvie Lesage Source Type: research